Current read
Clinical traction from 69 study records, 100 active source records, 13 rapid briefs, and 1 timeline events. Evidence maturity is 79/100, human translation signal is 70/100, and frontier activity is extreme (85/100). Frontier activity means research movement, not settled human proof.
This lane has stronger human/clinical support, but still needs bounded claims.
Commercial bias penalty: 100/100. Confidence: 72/100. Frontier activity means research movement, not settled human proof.
Why this row matters
Chronic inflammatory tone, immunosenescence, autoimmunity signals, infection resilience, and safety tradeoffs. The map tracks whether this lane is moving from biological plausibility toward outcomes people can responsibly discuss.
Current human translation
Human translation is 100/100 based on human-facing studies, clinical/regulatory sources, claims, and published coverage.
Main approaches being tracked
Inflammation-risk framing, immune-modulating biologics, infection and vaccine context.
What would move this row up?
Current bottleneck
Replication, durability, and sharper endpoint evidence.
Milestones that would move this row up
Row movement
Mini timeline
Newest graph events across studies, sources, briefs, claims, and timeline records
Evidence that would change the map
- Raise evidence maturity from 79/100 with better controlled studies or stronger replication.
- Raise human translation from 100/100 with outcomes that matter in people, not only biomarkers or mechanisms.
- Preserve safety discipline with clearer limitations, contraindications, and overclaim boundaries as activity grows.
What not to overclaim
- Do not use inflammation as a universal villain word.
- Do not present immune modulation as simple immune boosting.
Research map
Related studies
Study records matched through topic tags, intervention IDs, source IDs, related content, or row-specific tags.
Sleep and Inflammation Review
Sleep and inflammation: partners in sickness and in health
Review from 2019 in Nature Reviews Immunology, translated into key findings, limitations, and consumer relevance.
Nature Reviews Immunology / 2019->
Linoleic Acid Inflammation Review
Effect of dietary linoleic acid on markers of inflammation in healthy persons: a systematic review of randomized controlled trials
Systematic review from 2012 in Journal of the Academy of Nutrition and Dietetics, translated into key findings, limitations, and consumer relevance.
Journal of the Academy of Nutrition and Dietetics / 2012->
FDA Sunscreen Proposed Order
Questions and Answers: FDA posts deemed final order and proposed order for over-the-counter sunscreen
Government safety page from 2021 in U.S. Food and Drug Administration, translated into key findings, limitations, and consumer relevance.
U.S. Food and Drug Administration / 2021->
JAMA Sunscreen Absorption Pilot
Effect of sunscreen application on plasma concentration of sunscreen active ingredients
Clinical trial from 2019 in JAMA, translated into key findings, limitations, and consumer relevance.
JAMA / 2019->
JAMA Sunscreen Absorption Follow-up
Effect of sunscreen application under maximal use conditions on plasma concentration of sunscreen active ingredients
Clinical trial from 2020 in JAMA, translated into key findings, limitations, and consumer relevance.
JAMA / 2020->
CDC skin cancer prevention
How to prevent skin cancer
Government safety page from 2025 in Centers for Disease Control and Prevention, translated into key findings, limitations, and consumer relevance.
Centers for Disease Control and Prevention / 2025->
FDA tanning risks
Risks of tanning
Government safety page from 2026 in U.S. Food and Drug Administration, translated into key findings, limitations, and consumer relevance.
U.S. Food and Drug Administration / 2026->
AAD vitamin D statement
Vitamin D and UV exposure
Clinical guidance from 2026 in American Academy of Dermatology, translated into key findings, limitations, and consumer relevance.
American Academy of Dermatology / 2026->
CDC: About Community Water Fluoridatio
CDC: About Community Water Fluoridation
Government safety page from 2024 in Centers for Disease Control and Prevention, translated into key findings, limitations, and consumer relevance.
Centers for Disease Control and Prevention / 2024->
Useful source library entries
Related briefs
FDA Is Reviewing Compounded Peptide-Clinic Favorites
FDA's July advisory meeting covers BPC-157, Semax, Epitalon-related substances, MOTS-c, TB-500, KPV, DSIP/emideltide, and other peptide-related bulk substances popular in longevity circles.
Why now
The FDA calendar puts several longevity-clinic peptide favorites into a formal public regulatory review window.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
FDA Flagged a Serious Omnipod Insulin-Delivery Recall
Certain Omnipod Pods may leak insulin because of a cannula tear, creating under-delivery risk that can lead to hyperglycemia or diabetic ketoacidosis.
Why now
FDA's Class I classification makes this an urgent patient-safety story for insulin-dependent diabetes users who may have affected Pods.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
FDA Warns on Unapproved Cell and Tissue Products After Death Reports
FDA says unapproved human cell and tissue products marketed online may pose serious risks, including reports of patient deaths after use.
Why now
The gray-market regenerative medicine boom needs a clean evidence boundary alongside real cell and gene therapy breakthroughs.
- Overclaim risk
- medium-high
- Primary source
- Official
- Published
- Jun 30, 2026
FDA Expands Tzield to Newly Diagnosed Children With Type 1 Diabetes
Tzield can now be used to delay insulin-production decline in certain children ages 8 to 17 recently diagnosed with stage 3 type 1 diabetes.
Why now
T1D is shifting from only insulin replacement to immune-timing and beta-cell preservation stories.
- Overclaim risk
- medium-high
- Primary source
- Official
- Published
- Jun 30, 2026
GLP-1 Drugs Linked to Higher Smell and Taste Disturbance Risk
A large EHR cohort study found GLP-1 RA users with type 2 diabetes had higher documented smell and taste disturbance risk, though absolute rates were low.
Why now
GLP-1 safety signals are socially viral and need careful absolute-risk framing.
- Overclaim risk
- medium-high
- Primary source
- Primary
- Published
- Jun 30, 2026
FDA Panel Will Review Popular Longevity Peptides Amid Safety and Evidence Concerns
FDA advisers will review whether several popular peptides should be allowed for certain pharmacy compounding uses, while FDA materials flag limited human evidence and potential safety or quality concerns.
Why now
The peptide gray market just got a real FDA spotlight: BPC-157, TB-500, MOTS-c, Semax, and Epitalon are heading into a public review.
- Overclaim risk
- high
- Primary source
- Regulatory
- Published
- Jun 30, 2026
Latest graph movement
2026-06-26 / safety
EMA recommends Tavneos authorization revocation
EMA's reported recommendation put Tavneos into a benefit-risk, liver-safety, and clinical-trial-integrity review lane while final EU action remained pending.
Related published coverage
Published coverage contributes to coverage depth, not evidence maturity by itself.
Does Cannabis Shrink Your Brain?
A viral claim turns cannabis brain research into a one-line shrinkage scare. The evidence is messier: blood flow, activation, volume, cognition, age, dose, and heavy-use patterns are not interchangeable.
VV Signal Score
58
Early or context-dependent
- Sources
- 10
- Studies
- 7
- Claims
- 7
Fluoride: Cavity Shield or IQ Risk?
Fluoride discourse has collapsed dental benefit, child neurodevelopment, fluorosis, ethics, and institutional trust into one chaotic fight.
VV Signal Score
65
Promising signal
- Sources
- 12
- Studies
- 12
- Claims
- 10
Mold Toxicity: Real Indoor-Air Problem or Universal Symptom Funnel?
Mold exposure can matter for respiratory health, asthma, allergies, and vulnerable groups. That does not make every vague symptom proof of CIRS or a binder deficiency.
VV Signal Score
60
Early or context-dependent
- Sources
- 13
- Studies
- 13
- Claims
- 10
Mouth Taping: Nasal-Breathing Hack or Sleep-Apnea Red Flag?
Mouth taping looks ridiculous enough to go viral and plausible enough to sell. The evidence is narrow, the risks are underplayed, and snoring deserves more respect.
VV Signal Score
47
Mixed signal
- Sources
- 11
- Studies
- 11
- Claims
- 10
Perineum Tanning Is WellnessTok Sunlight Logic Gone Feral
Sunlight can affect circadian rhythm and vitamin D biology. Perineum sunning has viral claims, thin direct evidence, and a bad risk-reward profile.
VV Signal Score
25
Weak signal
- Sources
- 10
- Studies
- 10
- Claims
- 10
Seed Oils: Toxic Sludge or Internet Scapegoat?
Seed oils are blamed for inflammation, obesity, heart disease, and metabolic collapse. The stronger signal is not that linoleic-acid-rich oils are toxic. It is that they often travel inside ultra-processed food patterns.
VV Signal Score
55
Early or context-dependent
- Sources
- 7
- Studies
- 6
- Claims
- 10
Claim ledger
Related claims
Claim ledger records matched by topic, intervention, study, or source links.
glp 1: FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled
FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled products are different regulatory and quality-risk categories.
glp 1: Public GLP-1 claims are distorted by both promotional hype
Public GLP-1 claims are distorted by both promotional hype and categorical backlash, neither of which substitutes for indication-specific evidence.
sleep: Sleep disturbance has biologically plausible links to inflammatory and
Sleep disturbance has biologically plausible links to inflammatory and immune dysregulation through cytokine, neuroendocrine, autonomic, and antiviral-response pathways, but inflammation mediation between sleep and mortality is not settled.
seed oils: Seed oils are not supported as toxic at normal
Seed oils are not supported as toxic at normal dietary exposure, though the food pattern they often appear in can still be low-quality.
seed oils: The blanket claim that seed oils cause inflammation is
The blanket claim that seed oils cause inflammation is not supported by human trial-review evidence on linoleic acid and inflammatory markers in healthy adults.
seed oils: Omega-6 fats are not inherently pro-inflammatory in the simple
Omega-6 fats are not inherently pro-inflammatory in the simple viral sense; mechanistic plausibility does not override human outcome and marker evidence.